Our first priority is the health, wellness and safety of everyone who walks through our doors.

Bryn Mawr Medical Specialists Association is open for medically necessary office visits and procedures only. BMMSA as a corporation is taking all necessary precautions and following public health safety guidelines in regards to the COVID-19 pandemic.

TeleMedicine appointments are now available. Please contact your physicians office for eligibility, additional information, and with any concerns or questions.

If you are scheduled for an appointment with one of our doctors, we request that you call our office to reschedule your appointment if the answer is yes to any of the following questions:

  • Do you have a cough?
  • Do you have a fever?
  • Do you have any flu-like symptoms?
  • Do you have diarrhea?
  • Have you have traveled internationally in the past 14 days?
  • Have you had close contact with anyone who has traveled internationally in the past 14 days?

We encourage all of our patients to visit the CDC website and Main Line Health COVID-19 Response website to read more about everyday preventative measures and for the most up to date guidance regarding the Coronavirus (COVID-19). If you are concerned that you may have the Coronavirus (COVID-19), please contact your local Health Departments.

If you have any questions regarding our policy and your appointment, please call your doctor’s office.

Molly S. Stumacher, M.D.



  • Hematology

    Board Certified in 2008
  • Oncology

    Board Certified in 2007


Bryn Mawr Medical Arts Pavilion
825 Old Lancaster Road
Suite 440
Bryn Mawr, PA 19010
Phone: (610) 525-4511
Fax: (610) 525-8561

Education & Training

Medical School

Harvard Medical School, Boston, MA


Department of Medicine, Brigham and Women’s Hospital, Boston, MA


Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA


  • Bryn Mawr Hospital
  • Lankenau Hospital
  • Paoli Hospital

Clinical/Dept Titles

Attending Physician

Research Experience

  • CD40 antibody for the treatment of advanced solid tumors (Phase I study), PI: Robert Vonderheide, M.D., University of Pennsylvania Department of Hematology-Oncology, 2005-2006
  • CTLA4 antibody in the treatment of advanced breast cancer (Phase I study), PI: Susan Domchek, M.D., University of Pennsylvania Department of Hematology-Oncology, 2005-2006
  • The use of executive summaries in cancer patients’ consent to clinical trial enrollment (Phase II study), PI: Jane Weeks, M.D. and Steven Joffe, M.D., Dana Farber Cancer Institute, 2003


  • Vonderheide, RH, Flaherty KT, Khalil M, Stumacher MS, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83.
  • Stumacher, M, Domchek S. Update on chemoprevention in BRCA1and BRCA2 mutation carriers. Breast Cancer Online. 2005 Vol. 8 Issue 9.
Browse available departments: